Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.
EuroIntervention. 2017 Aug 25;13(6):706-716. doi: 10.4244/EIJ-D-17-00557.
The first percutaneous coronary intervention (PCI) was performed in September 1977 by Andreas Grüntzig using a rudimentary balloon angioplasty catheter mounted on a fixed wire. PCI was immediately recognised as a potential breakthrough in cardiovascular medicine, but uptake in clinical practice was limited by unpredictable acute outcomes and a need for surgical standby. The introduction of bare metal stents (BMS) in the 1980s improved procedure reproducibility and clinical outcomes through a permanent scaffolding of the coronary vessel, preventing abrupt occlusion and acute recoil. It was the introduction of drug-eluting stents (DES) at the beginning of this century, however, that allowed PCI to become one of the most frequently performed therapeutic interventions in medicine, primarily by addressing the issue of in-stent restenosis. DES technology has improved considerably since, with iterative developments of the stent metallic backbone, the polymer coating, and the released antiproliferative agents impacting on the safety and efficacy profile of these devices in a meaningful way. Overall, the impressive technological advances in metallic coronary stents have revolutionised the treatment of ischaemic heart disease over the last 40 years. The aim of the present article is to provide an overview of past, present, and future aspects of coronary stent technologies.
首例经皮冠状动脉介入治疗(PCI)于 1977 年 9 月由 Andreas Grüntzig 施行,他使用安装在固定导丝上的原始球囊血管成形术导管。PCI 立即被认为是心血管医学的潜在突破,但由于急性结果不可预测和需要手术备用,其在临床实践中的应用受到限制。20 世纪 80 年代,裸金属支架(BMS)的引入通过冠状动脉血管的永久性支架结构改善了手术的可重复性和临床结果,防止了突然闭塞和急性回缩。然而,正是本世纪初药物洗脱支架(DES)的引入,使得 PCI 成为医学上最常进行的治疗干预之一,主要通过解决支架内再狭窄问题。自那时以来,DES 技术取得了显著进展,支架金属骨架、聚合物涂层和释放的抗增殖剂的迭代发展,以有意义的方式影响这些设备的安全性和疗效。总体而言,过去 40 年来,金属冠状动脉支架的令人印象深刻的技术进步彻底改变了缺血性心脏病的治疗方法。本文旨在概述冠状动脉支架技术的过去、现在和未来。